

Press release May 25, 2026

VibroSense Dynamics receives regulatory approval in Singapore

VibroSense Dynamics AB (publ) announces today that VibroSense Meter® II has received regulatory approval in Singapore, listed as a Class A medical device with the Health Sciences Authority (HSA). The approval marks an important milestone in VibroSense's expansion into the Asia-Pacific region.

Singapore is one of Asia's leading medical technology hubs, known for its stringent regulatory standards and world-class healthcare system. The country serves as a strategic gateway to the broader Southeast Asian market, with a strong infrastructure for medical device distribution and a growing focus on chronic disease management, including diabetes and occupational health.

The listing confirms that VibroSense Meter® II meets Singapore's regulatory requirements for safety and performance. The device is used for objective and reproducible measurement of vibration perception in hands and feet, primarily for early detection of peripheral neuropathy.

"Regulatory approval in Singapore is an important step for VibroSense as we continue to expand our presence in Asia. The market has a strong clinical infrastructure and a clear need for better diagnostic tools within neurology and diabetes care", says Toni Speidel, CEO of VibroSense Dynamics AB.

For more information, please contact:

Toni Speidel, CEO

VibroSense Dynamics AB (publ)

Phone: +46 40 88 026

Email: info@vibrosense.com

Website: www.vibrosense.com

"The new Gold Standard for reliable detection of nerve damage"

About VibroSense Dynamics AB (publ)

VibroSense Dynamics AB (publ) develops and sells medical devices and services to facilitate diagnosis of nerve damage in the hands and feet. The method is based on measuring and quantifying the ability to perceive vibrations applied to the skin at multiple frequencies. The company's customers include diabetes clinics, occupational health providers, hospitals, primary care centers, and researchers.

Our vision that the company's products shall become a standard tool in all neurological examinations, to detect early signs of sensory changes so that patients and healthcare providers can take preventive action to avoid, reduce, or delay the onset of nerve damage in the hands and feet.